Trial Profile
A Phase 2, Randomized, Vehicle-controlled, Double-blind Study to Explore the Efficacy, Pharmacodynamics and Safety of Topical Ionic Contra-viral Therapy (ICVT) Comprised of Digoxin and Furosemide in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent Patients
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Jun 2019
Price :
$35
*
At a glance
- Drugs Digoxin/furosemide (Primary)
- Indications Human papillomavirus infections; Warts
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Cutanea Life Sciences
- 18 Mar 2019 Status changed from recruiting to discontinued.
- 13 Nov 2017 New trial record